Poor in vivo efficacy of caspofungin, micafungin and amphotericin B against wild-type Candida krusei clinical isolates does not correlate with in vitro susceptibility results

References

• Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133–163.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Neofytos D, Diekema D, et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the prospective antifungal therapy (PATH Alliance®) registry, 2004–2008. Diagn Microbiol Infect Dis. 2012;74:323–331.
   PubMed Web of Science ®Google Scholar
• Aversa F, Busca A, Candoni A, et al. Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use. J Chemother. 2017;29:131–143.
   PubMed Web of Science ®Google Scholar
• Baptista MI, Nona J, Ferreira M, et al. Invasive fungal infection in neonatal intensive care units: a multicenter survey. J Chemother. 2016;28:37–43.
   PubMed Web of Science ®Google Scholar
• Majoros L, Szegedi I, Kardos G, et al. Slow response of invasive Candida krusei infection to amphotericin B in a clinical time-kill study. Eur J Clin Microbiol Infect Dis. 2006;25:803–806.
   PubMed Web of Science ®Google Scholar
• Cantón E, Pemán J, Gobernado M, et al. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob Agents Chemother. 2004;48:2477–2482.
   PubMed Web of Science ®Google Scholar
• Perlin DS. Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. Drugs. 2014;74:1573–1585.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Executive summary: clinical practice guideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1–e50.
   PubMedGoogle Scholar
• Lortholary O, Renaudat C, Sitbon K, et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med. 2014;40:1303–1312.
   PubMed Web of Science ®Google Scholar
• Wang E, Farmakiotis D, Yang D, et al. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. J Antimicrob Chemother. 2015;70:2362–2368.
   PubMed Web of Science ®Google Scholar
• Colombo AL, Guimarães T, Sukienik T, et al. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med. 2014;40:1489–1498.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 3rd ed. M27-A3. Wayne, PA: CLSI; 2008.
   Google Scholar
• Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Update. 2011;14:164–176.
   PubMed Web of Science ®Google Scholar
• Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs. 2011;71:11–41.
   PubMed Web of Science ®Google Scholar
• Szabó Zs, Tóth B, Kovács M, et al. Evaluation of the new Micronaut-Candida system compared to the API ID32C method for yeast identification. J Clin Microbiol. 2008;46:1824–1825.
   PubMed Web of Science ®Google Scholar
• Földi R, Szilágyi J, Kardos G, et al. Effect of 50% human serum on the killing activity of micafungin against eight Candida species using time-kill methodology. Diagn Microbiol Infect Dis. 2012;73:338–342.
   PubMed Web of Science ®Google Scholar
• Földi R, Kovács R, Gesztelyi R, et al. Comparison of in vitro and in vivo efficacy of caspofungin against Candida parapsilosis, C. orthopsilosis, C. metapsilosis and C. albicans. Mycopathology. 2012;174:311–318.
   PubMedGoogle Scholar
• Kovács R, Gesztelyi R, Berényi R, et al. Killing rates exerted by caspofungin in 50% serum and its correlation with in vivo efficacy in a neutropenic murine model against Candida krusei and C. inconspicua. J Med Microbiol. 2014;63:186–194.
   PubMed Web of Science ®Google Scholar
• Domán M, Kovács R, Perlin DS, et al. Dose escalation studies with caspofungin against Candida glabrata. J Med Microbiol. 2015;64:998–1007.
   PubMed Web of Science ®Google Scholar
• Szilágyi J, Földi R, Bayegan S, et al. Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against Candida species using time-kill methodology. J Chemother. 2012;24:18–25.
   PubMed Web of Science ®Google Scholar
• Lewis RE, Wiederhold NP. The solubility ceiling: a rationale for continuous infusion amphotericin B therapy? Clin Infect Dis. 2003;37:871–872.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Vehreschild JJ, Vehreschild MJ, et al. Phase II dose escalation study of caspofungin for invasive aspergillosis. Antimicrob Agents Chemother. 2011;55:5798–5803.
   PubMed Web of Science ®Google Scholar
• Flattery AM, Hickey E, Gill CJ, et al. Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis. Antimicrob Agents Chemother. 2011;55:3491–3497.
   PubMed Web of Science ®Google Scholar
• Migoya EM, Mistry GC, Stone JA, et al. Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. J Clin Pharmacol. 2011;51:202–211.
   PubMed Web of Science ®Google Scholar
• Goto N, Hara T, Tsurumi H, et al. Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies. Am J Hematol. 2010;85:872–876.
   PubMed Web of Science ®Google Scholar
• Undre N, Stevenson P, Baraldi E. Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis. Eur J Drug Metab Pharmacokinet. 2012;37:31–38.
   PubMed Web of Science ®Google Scholar
• Grau S, Luque S, Campillo N, et al. Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. J Antimicrob Chemother. 2015;70:2854–2861.
   PubMed Web of Science ®Google Scholar
• Lempers VJ, Schouten JA, Hunfeld NG, et al. Altered micafungin pharmacokinetics in intensive care unit patients. Antimicrob Agents Chemother. 2015;59:4403–4409.
   PubMed Web of Science ®Google Scholar
• Yamada N, Kumada K, Kishino S, et al. Distribution of micafungin in the tissue fluids of patients with invasive fungal infections. J Infect Chemother. 2011;17:731–734.
   PubMed Web of Science ®Google Scholar
• Tascini C, Sozio E, Di Paolo A, et al. Fungicidal activity and PK/PD of caspofungin as tools to guide antifungal therapy in a fluconazole-resistant C. parapsilosis candidemia. J Chemother. 2017;15:1–4. doi:10.1080/1120009X.2017.1289308.
   Google Scholar
• Nasar A, Ryan L, Frei CR, et al. Influence of serum and albumin on echinocandin in vitro potency and pharmacodynamics. Curr Fungal Infect Rep. 2013;7:89–95.
   Google Scholar
• Maki K, Matsumoto S, Watabe E, et al. Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds. Microbiol Immunol. 2008;52:383–391.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Arendrup MC, Pfaller MA, et al. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother. 2013;57:5836–5842.
   PubMed Web of Science ®Google Scholar
• Prigitano A, Esposto MC, Tortorano AM. Comparison of effects of human serum and horse serum on in vitro susceptibility testing of echinocandins. J Chemother. 2014;26:62–63.
   PubMed Web of Science ®Google Scholar
• Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev. 2014;27:68–88.
   PubMed Web of Science ®Google Scholar